Medical Devices

Promising Phase 2 data shows a new DNA immunotherapy for advanced melanoma, delivered via a needle-free jet injector, significantly improves patient outcomes.

Amazon Pharmacy now offers the new Wegovy pill with transparent cash-pay options, shaking up the high-demand weight management drug market.

Automated Industrial Robotics Inc. acquires Ireland's KAON Automation, a strategic move to dominate the high-stakes medical and life sciences market.

After resolving manufacturing hurdles, Camurus' self-administered acromegaly treatment Oclaiz is back on track for US approval, promising new hope for patients.

Prescryptive and Ilant Health unveil a direct-to-employer model for obesity drugs, promising transparent pricing and better clinical outcomes for employers.

With new funding, Major Medical Devices is advancing a novel AAA repair device that uses arm access, promising safer procedures and wider patient eligibility.

Akari Therapeutics is advancing a new class of cancer drugs. Its unique PH1 payload kills tumors and activates the immune system, setting up a pivotal 2026.

With promising data in hard-to-treat cancers, iOnctura's lead drug, roginolisib, is set to make waves at the top healthcare investment forum.

With a massive $200M Series A and a promising Phase 2 drug, new biotech AirNexis aims to reshape the multi-billion dollar COPD treatment landscape.

After a major business sale, Elutia is launching NXT-41x, an antibiotic biomatrix designed to combat the high rate of infection in breast reconstruction.

Aesthetics firm Evolus reports its first profitable quarter and robust growth, banking on new products and international markets to defy industry slowdowns.

With a key drug in late-stage trials and a bolstered team, Palvella Therapeutics aims to deliver the first FDA-approved therapies for rare skin diseases.

With up to $80.8M in new funding, Curis is set to accelerate trials for emavusertib, a promising drug targeting some of the toughest blood cancers.

A new study reveals the hidden quality-of-life toll of a common virus on transplant patients, highlighting the urgent need for targeted new therapies.

Biocytogen and Acepodia are expanding their partnership to create next-gen ADCs with two targets and two warheads, aiming to defeat drug-resistant cancers.

An expanded partnership aims to create next-gen cancer therapies by combining bispecific antibodies with two distinct drugs to overcome tumor resistance.

Major insurers now cover advanced AI plaque analysis, paving the way for personalized heart attack prevention and a new standard of cardiovascular care.

Kezar Life Sciences faces a critical FDA meeting for its novel liver disease drug, a decision that could bring hope to patients and define the company's future.

Sanuwave Health posts record revenue, defying industry-wide turmoil as reimbursement cuts reshape the advanced wound care market. How did they do it?

Belgian biotech MRM Health gets the green light for a Phase 2b trial of MH002, a novel 'living drug' aimed at revolutionizing ulcerative colitis care.